Your browser is no longer supported. Please, upgrade your browser.
Settings
HOWL [NASD]
Werewolf Therapeutics, Inc.
Index- P/E- EPS (ttm)- Insider Own2.86% Shs Outstand27.54M Perf Week-14.70%
Market Cap381.97M Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month-
Income- PEG- EPS next Q- Inst Own1.68% Short Float- Perf Quarter-
Sales- P/S- EPS this Y- Inst Trans- Short Ratio- Perf Half Y-
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range13.03 - 23.99 Perf YTD-13.85%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-41.85% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low7.06% ATR2.62
Employees24 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)- Volatility10.72% -
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.08 Prev Close13.87
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume699.74K Price13.95
Recom- SMA20-7.93% SMA50-7.93% SMA200-7.93% Volume3,493 Change0.58%
Apr-30-21 04:44PM  
12:00PM  
Apr-29-21 09:19PM  
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sphera Global Healthcare Manag10% OwnerMay 04Buy16.00475,0007,600,000787,997May 04 01:21 PM
Longwood Fund III GP, LLC10% OwnerMay 04Buy16.00250,0004,000,0001,677,082May 04 04:30 PM
Arkin Bio Ventures 2 L.P.10% OwnerMay 04Buy16.00400,0006,400,0002,046,634May 04 04:31 PM
Asanuma SakaeDirectorMay 04Buy16.00312,5005,000,0002,068,909May 04 04:31 PM
Taiho Ventures LLC10% OwnerMay 04Buy16.00312,5005,000,0002,068,909May 04 04:31 PM
Lazarus AlonDirectorMay 04Buy16.00400,0006,400,0002,046,634May 04 04:30 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMay 04Buy16.001,715,00027,440,0003,524,758May 06 04:31 PM
MPM BioVentures 2014, L.P.10% OwnerMay 04Buy16.00125,7592,012,1443,187,998May 06 04:20 PM
GADICKE ANSBERT10% OwnerMay 04Buy16.00245,0003,920,0006,672,183May 06 04:19 PM
EVNIN LUKEDirectorMay 04Buy16.00150,7992,412,7844,284,172May 06 04:19 PM
Flynn James EPossible Member of 10% GroupMay 04Buy16.00800,00012,800,0002,552,787May 04 12:34 PM